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Summary of findings {#CD007952-sec1-0001}
===================

Summary of findings for the main comparisonSummary of findings table 1**Material incentives compared to routine care for improving patient adherence to TB managementPatient or population:** Recipients of TB control services **Settings:** Middle‐income and high‐income country settings (South Africa, Timore‐Leste, USA) **Intervention:** Material incentives (such as cash, grocery vouchers, or food) **Comparison:** Routine care**OutcomesIllustrative comparative risks\* (95% CI)Relative effect (95% CI)No of participants (trials)Quality of the evidence (GRADE)Assumed riskCorresponding riskRoutine careMaterial incentivesSustained incentive programmeCure or completion of treatment for active TB721 per 1000750 per 1000** (620 to 807)**RR 1.04** (0.97 to 1.13)4356 (2 trials)⊕⊕⊝⊝ **low^1^Completion of TB prophylaxis**------Not pooled869 (3 trials)⊕⊕⊝⊝ **low^2,3^Single once‐only incentiveReturn to clinic to start or continue treatment249 per 1000393 per 1000** (316 to 488)**RR 1.58** (1.27 to 1.96)595 (3 trials)⊕⊕⊕⊝ **moderate^4^Return for tuberculin skin test reading441 per 1000953 per 1000** (622 to 1000)**RR 2.16** (1.41 to 3.29)1371 (2 trials)⊕⊕⊝⊝ **low^5,6^**The **assumed risk** is taken from the control groups in the trials. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **CI:** confidence interval; **RR:** risk ratio.GRADE Working Group grades of evidence **High quality:** Further research is very unlikely to change our confidence in the estimate of effect. **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low quality:** We are very uncertain about the estimate.[^2]

Background {#CD007952-sec1-0002}
==========

Description of the condition {#CD007952-sec2-0001}
----------------------------

Tuberculosis (TB) is an infectious disease caused by the bacterium *Mycobacterium tuberculosis*, which spreads from person to person by inhalation of respiratory droplets. Although the global incidence of TB is falling, the burden of disease is still high, especially in low‐ and middle‐income countries (LMICs) where it is associated with poverty ([@CD007952-bbs2-0052]). Impaired immunity, due to co‐infection with the human immuno‐deficiency virus (HIV) or poor nutrition, plays an important role in many infections ([@CD007952-bbs2-0050]; [@CD007952-bbs2-0052]).

Following the initial infection, most people do not develop symptoms as *M. tuberculosis* bacteria are completely controlled by the immune system, and lie dormant in a state known as \'latent TB\'. Active TB, where the bacterium is no longer controlled by the immune system, can occur at any time following infection and most commonly affects the lungs, causing a chronic cough (which acts to spread the disease), loss of weight, loss of appetite, and general malaise ([@CD007952-bbs2-0028]).

The most widely used method of diagnosing latent TB is the tuberculin test (also known as the Mantoux test), which involves injecting a small amount of a purified *M. tuberculosis* protein under the skin, usually of the forearm. If the person has previously been exposed to TB, a small swelling occurs due to a localized immune response, and the size of this response is measured 48 to 72 hours later ([@CD007952-bbs2-0024]). Treatment of latent TB, often called TB prophylaxis, aims to prevent the later development of active disease, and reduce transmission.

Effective treatment for both active and latent TB requires regular medication to be taken for six to 12 months, and non‐adherence to this difficult and prolonged schedule is the most common cause of treatment failure ([@CD007952-bbs2-0041]; [@CD007952-bbs2-0045]). Non‐adherence, with prolonged infectiousness, constitutes a health risk to close family and community contacts, and can lead to the development of drug‐resistant organisms which are more difficult and more expensive to treat ([@CD007952-bbs2-0035]).

Adherence is not the sole responsibility of the patient, nor of the health system, but some combination of the two ([@CD007952-bbs2-0026]), and consequently interventions aimed at reducing non‐adherence may need to target both. These interventions may be classified as: technical (making the medications simpler to take, such as reducing doses and personalising packaging); behavioural (establishing a pattern of behaviour through stimuli or positive reinforcement); educational (improving patients\' capacity to manage their diseases, often through a cognitive didactic approach); structural (improving the accessibility and acceptability of TB programmes); or complex (a combination of these) ([@CD007952-bbs2-0029]; [@CD007952-bbs2-0040]; [@CD007952-bbs2-0044]; [@CD007952-bbs2-0049]). A review of direct observation has been completed indicating little added effect of direct observation ([@CD007952-bbs2-0031]), and a review of patient reminders and prompts is also available showing mixed effects ([@CD007952-bbs2-0037]). A further review found that patient education may improve completion of treatment for latent TB (no trials were found investigating the effect of patient education for active TB) ([@CD007952-bbs2-0038]).

Description of the intervention {#CD007952-sec2-0002}
-------------------------------

Incentives and enablers are interventions targeted at the patient which seek to either promote or assist improved adherence ([@CD007952-bbs2-0047]; [@CD007952-bbs2-0048]; [@CD007952-bbs2-0049]). They may be given directly as cash or vouchers for groceries, or indirectly as the provision of a service for which the patient would otherwise have had to pay (for example, transport to and from the clinic).

A recent overview of reviews found that material incentives improved adherence and outcomes for a number of health problems, and also increased the utilisation of health services for prevention programmes ([@CD007952-bbs2-0043]). Conditional cash transfers, used primarily in Latin America, are essentially material incentives used on a large scale to promote healthy behaviour in poor families and individuals ([@CD007952-bbs2-0034]). They have been particularly successful in promoting the use of health services and in improving nutritional and anthropometric outcomes in certain groups ([@CD007952-bbs2-0034]).

How the intervention might work {#CD007952-sec2-0003}
-------------------------------

Incentives are based on behavioural theories of reward for \'good\' behaviour ([@CD007952-bbs2-0044]), and may be defined as \"any financial or material reward that patients and/or providers receive, conditional on their explicitly measured performance or behavior\" ([@CD007952-bbs2-0023]). Alternatively, \'enablers\' assist patients to adhere by overcoming the financial barriers to treatment. In a recent qualitative review, economic constraints due to absences from work to attend appointments, or the direct and indirect costs of accessing treatment, were commonly cited by patients as important barriers to completing TB treatment ([@CD007952-bbs2-0040]).

As well as potential benefits, the use of material incentives and enablers may also have unintentional negative consequences. Patients who receive incentives to adhere to one health behaviour may be reluctant to adhere to others if they are not also accompanied by incentives ([@CD007952-bbs2-0004]). This might be especially important where incentives are offered in one of several possible stages in a multi‐stage treatment process such as screening for and treating TB. Further possible negative effects include: resentment in patients who do not receive the incentive ([@CD007952-bbs2-0005]); fraud and corruption, with patients manipulating the incentive system to gain more; or the creation of \'ghost\' patients allowing health staff to steal incentives from the system ([@CD007952-bbs2-0011]); or the \'perverse incentive\' effect, where the incentive induces exactly the opposite behaviour to that intended, ie patients who want to continue receiving the incentive may deliberately not take medications in order to remain ill.

Why it is important to do this review {#CD007952-sec2-0004}
-------------------------------------

In light of the increased risk of TB posed by HIV infection ([@CD007952-bbs2-0052]), and the development of epidemics of drug‐resistant forms of TB ([@CD007952-bbs2-0046]; [@CD007952-bbs2-0053]), efforts to help patients complete therapy are of paramount importance. If material incentives and enablers do improve adherence rates amongst patients with TB, they should be used far more widely than they are currently.

Objectives {#CD007952-sec1-0003}
==========

To evaluate the effects of material incentives and enablers given to patients undergoing diagnostic testing for TB, or receiving drug therapy to prevent or cure TB.

Methods {#CD007952-sec1-0004}
=======

Criteria for considering studies for this review {#CD007952-sec2-0005}
------------------------------------------------

### Types of studies {#CD007952-sec3-0001}

Randomized controlled trials (RCTs), where the unit of allocation is either an individual or cluster.

### Types of participants {#CD007952-sec3-0002}

People receiving curative treatment for active TB: smear positive cases, smear negative cases, new cases, and re‐treatment cases;People receiving preventive therapy for latent TB: patients at risk of developing active TB and taking anti‐TB chemoprophylaxis (ie isoniazid preventive therapy);People suspected of TB undergoing, and collecting results of, diagnostic tests: diagnosis of TB infection (using tuberculin skin tests) and disease (using sputum microscopy and culture) often requires the patient to return to the health facility a few days after the test is performed to receive the results. Incentives have been used to encourage patients to do this.

### Types of interventions {#CD007952-sec3-0003}

#### Intervention {#CD007952-sec4-0001}

Interventions included any form of material inducement to return for TB test results, or adhere to or complete anti‐TB preventive or curative treatment. These may have been direct such as cash or vouchers for groceries, or indirect such as the provision of a service for which the patient would otherwise have had to pay (for example, transport to and from the clinic). We did not consider non‐material incentives, such as praise from a health worker, in this Cochrane Review, because their economic value is difficult to quantify and the form of the incentive is difficult to standardize.

In those trials where incentives were combined with other interventions, studies were only eligible for inclusion in a meta‐analysis if disaggregation of the effect of the incentive was possible. Other interventions that could be combined with incentives include health information and education, and increased access to health workers through home visits, or additional appointments.

We only included trials if the standard TB curative or preventive treatment was the same across the control and treatment arms.

#### Control {#CD007952-sec4-0002}

Controls were those patients receiving standard TB treatment or preventive treatment, or undergoing testing for suspected TB, who had no incentive or an alternative incentive or intervention.

### Types of outcome measures {#CD007952-sec3-0004}

#### Primary outcomes {#CD007952-sec4-0003}

**For treatment of active TB:** Cure or completion of treatment, or both, using the following World Health Organization (WHO) definitions ([@CD007952-bbs2-0051]):

**Cured:** a patient who was initially smear‐positive and who was smear negative in the last month of treatment and on at least one previous occasion;**Completed treatment:** a patient who completed the course of treatment as prescribed by the health worker;**Successfully treated:** a patient who was cured or who completed treatment ([@CD007952-bbs2-0051]).

**For prophylaxis:** cases of active TB; completion of prophylactic treatment.

**For diagnostics:** number returning to collect test results within the appropriate time frame for that test.

#### Secondary outcomes {#CD007952-sec4-0004}

Appointment keeping, presence of urinary markers, and certification by direct observation of treatment.

##### Adverse events {#CD007952-sec5-0001}

Adverse events reported in trials, such as expenditure of cash or vouchers on unhealthy items. The latter were defined as commodities that undermine the patient\'s chance of cure, such as tobacco products or alcohol.

##### Costs {#CD007952-sec5-0002}

Cost effectiveness of the intervention; where costs include the direct and indirect costs incurred by patients, and costs to the health system of providing and administering the incentives.

Search methods for identification of studies {#CD007952-sec2-0006}
--------------------------------------------

We attempted to identify all relevant trials regardless of language or publication status (published, unpublished, in press, and in progress).

### Electronic searches {#CD007952-sec3-0005}

For this review update we searched the following databases using the search terms and strategy described in [Table 7](#CD007952-tbl-0007){ref-type="table"}: Cochrane Infectious Diseases Group Specialized Register (5 June 2015); Cochrane Central Register of Controlled Trials (CENTRAL: 5 June 2015); MEDLINE (1966 to 5 June 2015); EMBASE (1974 to 5 June 2015); LILACS (1982 to 5 June 2015); and Science Citation Index (EXPANDED) and Social Sciences Citation index (SSCI) (1956 to 5 June 2015).Table 1Detailed search strategies**Search setCIDG SR^a^CENTRALMEDLINE^b^EMBASE^b^LILACS^b^SCI‐EXPANDED and SSC**1tuberculosistuberculosistuberculosistuberculosistuberculosistuberculosis2adherencePATIENT COMPLIANCEPATIENT COMPLIANCEPATIENT‐COMPLIANCEadherenceadherence3compliancePATIENT DROPOUTSPATIENT DROPOUTSTREATMENT‐REFUSALcompliancecompliance4Monitor\*MOTIVATIONMOTIVATIONMOTIVATIONMonitor\$Monitor\*5Incentive\*SOCIAL SUPPORTSOCIAL SUPPORTSOCIAL SUPPORTIncentive\$Incentive\*6Reward\*CONTRACTSCONTRACTSCOMPENSATIONReward\$Reward\*7Voucher\*AdherenceAdherenceAdherenceVoucher\$Voucher\*8Payment\*Incentive\*Incentive\*Incentive\$Payment\$Payment\*9Reimbursement\*Reward\*Reward\*Reward\$Reimbursement\$Reimbursement\*10ConcordanceVoucher\*Voucher\*Voucher\$ConcordanceConcordance11Cash transfer\*Payment\*Payment\*Payment\$Cash transfer\$Cash transfer\*122‐11/ORReimbursement\*Reimbursement\*Reimbursement\$2‐11/OR2‐11/OR131 AND 12ConcordanceConcordanceConcordance1 AND 121 AND 1214---Cash transfer\*Cash transfer\*Cash transfer\$------15---2‐14/OR2‐14/OR2‐14/OR------16---1 AND 151 AND 151 AND 15------17------Limit 16 to HumanLimit 16 to Humans------[^3]

We also searched the metaRegister of Controlled Trials (mRCT) using \'tuberculosis\', \'incentive\', \'cash transfer\', \'adherence\', \'compliance\', and \'concordance\' as search terms (1998 to 5 June 2015). In addition, we searched the WHO International Clinical Trials Registry Platform (http://www.who.int/ictrp/search/en/) for ongoing trials (5 June 2015).

This is the same search strategy and the same databases that were used for the original review, [@CD007952-bbs2-0054].

### Searching other resources {#CD007952-sec3-0006}

#### Researchers and organizations {#CD007952-sec4-0005}

We contacted researchers and other experts in the field of TB and adherence research for unpublished and ongoing trials.

#### Reference lists {#CD007952-sec4-0006}

We checked the reference lists of related reviews ([@CD007952-bbs2-0026]; [@CD007952-bbs2-0029]; [@CD007952-bbs2-0034]; [@CD007952-bbs2-0043]; [@CD007952-bbs2-0045]) and all full‐text articles reviewed for inclusion in this review.

Data collection and analysis {#CD007952-sec2-0007}
----------------------------

### Selection of studies {#CD007952-sec3-0007}

For the original 2012 review, [@CD007952-bbs2-0054], Elizabeth Lutge (EL) and Stephen Knight (SK) independently screened all citations and abstracts identified by the search strategy for potentially eligible studies ([@CD007952-bbs2-0054]). For this review update, EL and Charles Shey Wiysonge (CSW) independently performed screening and study selection. Two review authors independently assessed the full text articles of potentially relevant studies using the pre‐specified trial inclusion criteria. We resolved any disagreements by discussion and consensus. When a disagreement could not be resolved we sought arbitration from a third review author; CSW in the case of the original Cochrane review and Jimmy Volmink (JV) for both the original, [@CD007952-bbs2-0054], and this Cochrane review update. We excluded studies that did not meet the inclusion criteria and documented the reasons for exclusion in the \'[Characteristics of excluded studies](#CD007952-sec2-0023){ref-type="sec"}\' table.

As EL is the author of a trial included in this Cochrane review update, two review authors who were not involved with this trial (David Sinclair (DS) and CSW) independently applied the inclusion criteria, assessed risk of bias, and performed data extraction of this trial. Two Cochrane Editors provided oversight.

### Data extraction and management {#CD007952-sec3-0008}

In both the original review and its update, EL and CSW independently extracted information from the selected trial reports using a pre‐designed data extraction form on study methods used, participant characteristics, interventions, and outcomes. For all outcomes, we extracted the number of participants randomized and the number analysed. For each study, we extracted the number of participants with an outcome of interest in each group as well as the number of participants randomized to each group, and the number analysed.

We resolved any disagreements through discussion and consensus between EL and CSW initially, and with SK or JV if the disagreement was not resolved.

### Assessment of risk of bias in included studies {#CD007952-sec3-0009}

EL, CSW, and DS independently assessed the risk of bias in each included trial using Cochrane\'s \'Risk of bias\' assessment tool ([@CD007952-bbs2-0030]), in line with the Cochrane policy on trialists who are also review authors ([@CD007952-bbs2-0032]). We followed the guidance to assess whether adequate steps were taken to reduce the risk of bias across six specific domains, namely: random sequence generation; allocation concealment; blinding of participants, personnel, and outcome assessment; incomplete outcome data; selective outcome reporting; and \'other issues\'. For each included trial, we independently described what the trial authors reported that they did for each domain and then made a decision relating to the risk of bias for that domain by assigning a judgement of either \'low\', \'high\', or \'unclear\' risk of bias. EL, CSW, and DS compared the results of their independent \'Risk of bias\' assessments and resolved any discrepancies by discussion and consensus. A fourth review author (JV) resolved any differences in opinion.

### Assessment of reporting biases {#CD007952-sec3-0010}

If at least 10 trials were included in the meta‐analysis for any outcome, we would have evaluated the likelihood of publication bias and other sources of bias by examining the degree of asymmetry of funnel plots. We chose this number because it has been shown that when there are fewer than 10 studies in a meta‐analysis the power of funnel plot asymmetry tests is too low to distinguish chance from real asymmetry ([@CD007952-bbs2-0030]).

### Data synthesis {#CD007952-sec3-0011}

We analysed data using [@CD007952-bbs2-0042]. We analysed trial participants in groups to which they were randomized, regardless of how much of the intended intervention they actually received.

All studies reported only dichotomous data, so we have expressed study results as the risk ratio (RR) with its 95% confidence intervals (CI) for each outcome. We used the fixed‐effect model for the primary analysis. When significant statistical heterogeneity was present and it was appropriate to combine the data, we used the random‐effects model. We stratified analyses according to the type of incentive and control intervention, that is, incentive versus routine care, immediate versus deferred incentive, cash versus non‐cash incentive, and incentive versus any other intervention.

In addition, we used the GRADE approach to summarise the quality of the evidence on the effects of material incentives on each outcome ([@CD007952-bbs2-0027]). In the GRADE system, randomized trials without important limitations constitute high quality evidence. However, the system considers five factors that can lower the quality of the evidence: study limitations; inconsistent results across studies; indirectness of the evidence; imprecision; and publication bias. Overall, the GRADE system classifies research evidence into four categories (high, moderate, low, or very low quality). High quality evidence implies that we \"are very confident that the true effect lies close to that of the estimate of the effect\", while very low quality evidence implies that the \"true effect is likely to be substantially different from the estimate of effect\" found in the review ([@CD007952-bbs2-0022]).

### Subgroup analysis and investigation of heterogeneity {#CD007952-sec3-0012}

We determined the presence of statistical heterogeneity across trials by visually inspecting the forest plots to check for overlapping CIs and by means of the Chi² test for heterogeneity with a P value of \< 0.10 indicating statistical significance. Furthermore, we use the I² statistic to quantify the amount of heterogeneity as either low (I² statistic value ≤ 25%), moderate (I² statistic value between 25% and 75%), or high (I² statistic value of ≥ 75%). If we had at least 10 studies in any meta‐analysis that showed significant statistical heterogeneity, we would have explored the possible sources of heterogeneity by performing subgroup analyses; with subgroups defined by age, gender, socioeconomic status, and risk of bias (low versus high/unclear).

Results {#CD007952-sec1-0005}
=======

Description of studies {#CD007952-sec2-0008}
----------------------

For [@CD007952-bbs2-0054], we obtained 733 titles and abstracts from the electronic search of databases, and no additional articles from contacting researchers or screening reference lists. After removal of duplicates, 225 records remained. Following discussion and consensus, we obtained 21 potentially eligible articles. Eleven RCTs met our inclusion criteria ([@CD007952-bbs2-0001]; [@CD007952-bbs2-0003]; [@CD007952-bbs2-0004]; [@CD007952-bbs2-0005]; [@CD007952-bbs2-0006]; [@CD007952-bbs2-0007]; [@CD007952-bbs2-0008]; [@CD007952-bbs2-0009]; [@CD007952-bbs2-0010]; [@CD007952-bbs2-0011]; [@CD007952-bbs2-0012]). The final article, [@CD007952-bbs2-0033], was a cost‐effectiveness analysis of an included study ([@CD007952-bbs2-0007]).

In the 2014 update to the review, we obtained five records from the searches. We screened the abstracts of theses publications and deemed three irrelevant (one was a report of an education intervention and two were reports of text messaging interventions for improving TB treatment adherence). Two full articles were retrieved ([@CD007952-bbs2-0017]; [@CD007952-bbs2-0002]). We excluded [@CD007952-bbs2-0017] because it was not a RCT; it used an historical control group as comparator ([@CD007952-bbs2-0017]). We included the second potentially eligible study, [@CD007952-bbs2-0002], in this review. The search conducted in 2015 yielded 11 records, seven published articles, and four ongoing studies. Of the seven published articles, five were clearly irrelevant to this review and were excluded. One of the remaining two articles reported a qualitative process evaluation of an included study ([@CD007952-bbs2-0002]). The other article reported data from an observational cohort study ([@CD007952-bbs2-0015]), and excluded because it was not a RCT. All four ongoing studies were found to be irrelevant to the review and discarded.

The search and selection of studies for the original review, [@CD007952-bbs2-0054], and its update are shown in [Figure 1](#CD007952-fig-0001){ref-type="fig"}.Figure 1PRISMA diagram showing the search and selection of studies

### Included studies {#CD007952-sec3-0013}

The trials identified and included in this review all randomized individual participants and reported only dichotomous outcomes.

Ten of the 12 included trials were conducted in the USA, and only two are from low‐ and middle‐income countries (LMICs) ([@CD007952-bbs2-0002]: South Africa; [@CD007952-bbs2-0006]: Timor‐Leste).

Studies varied in size from 79 to 4091 participants, with a mean of 735 participants, and most studies focused on very specific patient subgroups. Four studies were conducted among injection drug or cocaine users ([@CD007952-bbs2-0003]; [@CD007952-bbs2-0004]; [@CD007952-bbs2-0001]; [@CD007952-bbs2-0005]), three among homeless or marginally housed adults ([@CD007952-bbs2-0008]; [@CD007952-bbs2-0009]; [@CD007952-bbs2-0010]), two studies in prisoners ([@CD007952-bbs2-0011]; [@CD007952-bbs2-0012]), and one assessed incentives given to adolescents aged 11 to 19 years ([@CD007952-bbs2-0007]). Only two studies involved members of the general adult population with TB ([@CD007952-bbs2-0002]; [@CD007952-bbs2-0006]).

The studies assessed adherence to different stages of TB management. Some investigated the use of incentives in improving return for reading of tuberculin skin test results ([@CD007952-bbs2-0003]; [@CD007952-bbs2-0004]) while others focused on improving attendance at the clinic for initiation of treatment ([@CD007952-bbs2-0008]), adherence to preventive TB treatment ([@CD007952-bbs2-0001]; [@CD007952-bbs2-0005]; [@CD007952-bbs2-0007]; [@CD007952-bbs2-0011]; [@CD007952-bbs2-0012]; [@CD007952-bbs2-0009]; [@CD007952-bbs2-0010]) and two looked at adherence to treatment for active TB ([@CD007952-bbs2-0002]; [@CD007952-bbs2-0006]).

The trials investigated various types of incentives, and several trials had multiple study arms receiving different forms of both material and non‐material incentives. Eight studies included a study arm given cash in values of USD 5 or USD 10 ([@CD007952-bbs2-0001]; [@CD007952-bbs2-0003]; [@CD007952-bbs2-0004]; [@CD007952-bbs2-0005]; [@CD007952-bbs2-0008]; [@CD007952-bbs2-0009]; [@CD007952-bbs2-0010]; [@CD007952-bbs2-0011]). Four studies gave vouchers that could be redeemed for groceries, food, transport, meals at fast food outlets or phone calls ([@CD007952-bbs2-0002]; [@CD007952-bbs2-0004]; [@CD007952-bbs2-0010]; [@CD007952-bbs2-0012]), and one study gave food as a hot daily meal ([@CD007952-bbs2-0006]). In one trial, adolescent patients negotiated the incentive they received from their parents ([@CD007952-bbs2-0007]). Common choices included special meals at home, going to a movie, or renting a video.

These material incentives were compared with routine care, and in multi‐arm trials also with motivational education ([@CD007952-bbs2-0003]; [@CD007952-bbs2-0004]), peer counselling ([@CD007952-bbs2-0007]; [@CD007952-bbs2-0008]; [@CD007952-bbs2-0009]), and standardized education sessions ([@CD007952-bbs2-0011]; [@CD007952-bbs2-0012]). In addition, one study compared different levels of incentive ([@CD007952-bbs2-0003]), one study compared an immediate incentive, given monthly throughout treatment, with a lump sum given on completion ([@CD007952-bbs2-0001]), and two studies compared different forms of incentive ([@CD007952-bbs2-0004]; [@CD007952-bbs2-0010]).

### Excluded studies {#CD007952-sec3-0014}

We excluded trials for the following reasons: patients in both trial arms were given the same incentive ([@CD007952-bbs2-0020]); quasi‐randomized with randomization done either by day of the week ([@CD007952-bbs2-0014]) or by the last digits in the participants\' clinic record numbers ([@CD007952-bbs2-0019]); cross sectional studies where one group was given the incentive and the other was not ([@CD007952-bbs2-0013]; [@CD007952-bbs2-0016]; [@CD007952-bbs2-0021]); or the main intervention was community health‐worker delivered TB treatment combined with food supplements ([@CD007952-bbs2-0018]). In this review update, we excluded one new potentially eligible study because the control was an historical group of patients on treatment for TB ([@CD007952-bbs2-0017]), and another study because the intervention was not randomized ([@CD007952-bbs2-0015]).

Risk of bias in included studies {#CD007952-sec2-0009}
--------------------------------

We have summarized our \'Risk of bias\' judgements for each included trial in [Figure 2](#CD007952-fig-0002){ref-type="fig"} and [Figure 3](#CD007952-fig-0003){ref-type="fig"}.Figure 2Risk of bias graph: review authors\' judgements about each risk of bias item presented as percentages across all included studies.Figure 3Risk of bias summary: review authors\' judgements about each risk of bias item for each included study.

### Allocation {#CD007952-sec3-0015}

We considered the generation of the randomization sequence adequate in nine trials ([@CD007952-bbs2-0001]; [@CD007952-bbs2-0002]; [@CD007952-bbs2-0005]; [@CD007952-bbs2-0006]; [@CD007952-bbs2-0008]; [@CD007952-bbs2-0009]; [@CD007952-bbs2-0010]; [@CD007952-bbs2-0011]; [@CD007952-bbs2-0012]) and unclear risk in the remainder ([@CD007952-bbs2-0003]; [@CD007952-bbs2-0004]; [@CD007952-bbs2-0007]). Allocation concealment was judged to be adequate in five trials ([@CD007952-bbs2-0002]; [@CD007952-bbs2-0005]; [@CD007952-bbs2-0006]; [@CD007952-bbs2-0011]; [@CD007952-bbs2-0012]) and unclear risk in the rest.

### Blinding {#CD007952-sec3-0016}

Three trials had adequate blinding of outcome assessors ([@CD007952-bbs2-0011]; [@CD007952-bbs2-0012]; [@CD007952-bbs2-0010]), [@CD007952-bbs2-0002] had no blinding of outcome assessors, and the remaining trials were unclear.

### Incomplete outcome data {#CD007952-sec3-0017}

All the included trials addressed incomplete outcome data adequately.

### Selective reporting {#CD007952-sec3-0018}

It was unclear to us whether or not 11 of the 12 included RCTs were free of selective outcome reporting since the study protocols were unavailable and there was no earlier methods paper listing the pre‐specified outcomes for any of the trials. The one trial which was prospectively registered prior to commencement (Current Controlled Trials ISRCTN50689131) was free of selective reporting ([@CD007952-bbs2-0002]).

### Other potential sources of bias {#CD007952-sec3-0019}

[@CD007952-bbs2-0010] compared the effects of cash and non‐cash incentives among homeless adults on adherence to treatment for latent TB infection as well as the length of time needed to look for participants who missed their dose of medications. Although the participants were described as homeless, the study groups were not the same with respect to their primary housing in the year prior to the study. In the cash incentive arm, 23% had lived in a shelter or on the street, whilst 41% of the non‐cash incentive arm had done so ([@CD007952-bbs2-0010]). This baseline difference had the potential to introduce systematic differences in study outcomes.

The conduct of the two trials amongst patients on treatment for active TB were affected by contextual issues that had important implications for their results ([@CD007952-bbs2-0002]; [@CD007952-bbs2-0006]). In Martin\'s trial, two important factors affected the conduct of the trial and undermined the potential effectiveness of the intervention. The first was civil conflict that arose during the last few months of the trial, resulting in the displacement of approximately 70% of the local population, and dramatically increasing the rate of default from treatment ([@CD007952-bbs2-0006]). The second factor was the timing of the provision of meals to patients in the intervention group. Many patients found the provision of meals, together with treatment, at midday inconvenient, and this may have become a barrier to adherence to treatment ([@CD007952-bbs2-0006]). In [@CD007952-bbs2-0002], fidelity to the intervention was poor, with only 31.5% of patients receiving their vouchers for most of their treatment. More than a third (36.2%) of eligible patients did not receive a voucher at all and the remainder received vouchers for between one and three months of treatment. This low fidelity was attributed largely to nurses\' rationing of the vouchers to those whom they felt were more deprived and therefore more deserving ([@CD007952-bbs2-0002]). It is important that such contextual issues be considered in further trials of this nature. In the very environments where extensive poverty or conflicts prevail and TB is likely to be more prevalent, contextual issues may profoundly affect the conduct and the results of the trials.

Effects of interventions {#CD007952-sec2-0010}
------------------------

See: [Table 1](#CD007952-tbl-0001){ref-type="table"}

### Incentives versus routine care {#CD007952-sec3-0020}

#### Completion of treatment for active TB {#CD007952-sec4-0007}

Two trials examined the effect of material incentives in patients with active TB. One trial evaluated incentives given as food (in the form of hot meals at the clinic during the intensive phase of treatment followed by monthly food parcels) compared to usual care with nutritional advice ([@CD007952-bbs2-0006]), and the second trial compared vouchers, redeemable for food and household goods, with usual care alone ([@CD007952-bbs2-0002]). Neither trial found statistically significant differences in treatment completion rates between participants given incentives and those receiving usual care (RR 1.04, 95% CI 0.97 to 1.14; two trials, 4356 participants; [Analysis 1.1](#CD007952-fig-00101){ref-type="fig"}).

#### Completion of TB prophylaxis {#CD007952-sec4-0008}

Three studies from the USA examined the effect of incentives on completion of TB prophylaxis. [@CD007952-bbs2-0005] gave a USD 5 cash incentive to drug users on attendance for twice weekly directly observed treatment, [@CD007952-bbs2-0007] established an incentive agreement between adolescents aged between 11 to 19 years and their parents, where parents provided cash or treats at various stages in the treatment process, and [@CD007952-bbs2-0012] gave recently released prisoners transportation vouchers worth USD 25 upon first presentation at a TB clinic.

[@CD007952-bbs2-0005] showed large effects with incentives, with over half the 53 patients completing treatment with an incentive, contrasted with very low completion in the control (2/55). In [@CD007952-bbs2-0007], completion of treatment was better in the control group (77.8%), and was similar with the incentive (76.4%), while in [@CD007952-bbs2-0012] completion remained low in both groups despite the intervention (13.8% control versus 14.1% intervention).

#### Return to clinic for initiation or continuation of TB prophylaxis {#CD007952-sec4-0009}

Three studies from the USA compared material incentives with routine care ([@CD007952-bbs2-0008]; [@CD007952-bbs2-0011]; [@CD007952-bbs2-0012]). [@CD007952-bbs2-0008] gave USD 5 to homeless people on return to a clinic after a positive tuberculin skin test, [@CD007952-bbs2-0011] gave USD 5 when recently released prisoners attended a community clinic for continuation of TB prophylaxis, and [@CD007952-bbs2-0012] gave recently released prisoners food or transportation vouchers worth USD 25 upon presentation at a TB clinic.

Incentives improved clinic attendance for initiation or continuation of treatment for latent TB infection (RR 1.58, 95% CI 1.27 to 1.96; three trials, 595 participants; [Analysis 1.3](#CD007952-fig-00103){ref-type="fig"}). Completion rates in the control groups varied, and this was also the case in the intervention group, so that despite the apparent benefit in terms of relative risk, in two trials in prisoners, attendance at clinics remained lower than 25% even in the intervention groups.

#### Return to clinic for tuberculin skin test reading {#CD007952-sec4-0010}

Two studies in drug users from the USA compared material incentives (USD 5 to USD 10) with routine care alone ([@CD007952-bbs2-0003]; [@CD007952-bbs2-0004]).

Material incentives increased the proportion of people who returned for reading of the tuberculin skin test (RR 2.16, 95% CI 1.41 to 3.29; two trials, 1371 participants; [Analysis 1.4](#CD007952-fig-00104){ref-type="fig"}), both with quantitatively important large effects.

### Immediate versus deferred incentive {#CD007952-sec3-0021}

#### Completion of TB prophylaxis {#CD007952-sec4-0011}

One study among drug users ([@CD007952-bbs2-0001]), compared the effects of an immediate incentive (USD 10 for each monthly appointment attended) with the promise of a deferred lump sum (USD 10 for each appointment attended) on completion of TB prophylaxis.

The participants who received the immediate incentives completed treatment more often than those whose incentives were deferred (83% versus 75%), but the difference was not statistically significant (RR 1.11, 95% CI 0.98 to 1.24; one trial, 300 participants; [Analysis 2.1](#CD007952-fig-00201){ref-type="fig"}).

### Cash versus non‐cash incentives {#CD007952-sec3-0022}

#### Completion of TB prophylaxis {#CD007952-sec4-0012}

One study among homeless and marginally housed adults with latent TB infection ([@CD007952-bbs2-0010]) compared a cash incentive (USD 5), with non‐cash incentives (patients could choose between fast food or grocery store coupons, phone cards or bus tokens equivalent to USD 5). The cash incentive was more effective than the non‐cash incentives (RR 1.26, 95% CI 1.02 to 1.56; one trial, 141 participants; [Analysis 3.1](#CD007952-fig-00301){ref-type="fig"}).

#### Return to clinic for tuberculin skin test reading {#CD007952-sec4-0013}

One study amongst injection drug and crack cocaine users ([@CD007952-bbs2-0004]), directly compared a cash incentive (USD 10) with non‐cash incentives (grocery store coupons, bus tokens and fast food coupons equivalent in value to USD 10).

The cash incentive was significantly more effective at increasing return for reading of tuberculin skin tests than any of the non‐cash incentives (RR 1.13, 95% CI 1.07 to 1.19; one trial, 652 participants; [Analysis 3.2](#CD007952-fig-00302){ref-type="fig"}).

### Different values of cash incentive {#CD007952-sec3-0023}

#### Return to clinic for tuberculin skin test reading {#CD007952-sec4-0014}

One trial, [@CD007952-bbs2-0003], also compared different values of cash incentive (USD 10 versus USD 5).

The USD 10 incentive significantly increased the proportion of patients returning to clinic to collect their TB test result compared to the USD 5 incentive (RR 1.08, 95% CI 1.01 to 1.16; one trial, 404 participants; [Analysis 5.1](#CD007952-fig-00501){ref-type="fig"}).

### Incentives versus any other intervention {#CD007952-sec3-0024}

#### Completion of TB prophylaxis {#CD007952-sec4-0015}

Three trials also used peer counselling or education sessions to promote completion of TB prophylaxis: one among jail inmates ([@CD007952-bbs2-0012]), one amongst homeless adults ([@CD007952-bbs2-0009]), and one among adolescents ([@CD007952-bbs2-0007]). There was no significant difference between material incentives and education or counselling (RR 1.04, 95% CI 0.59 to 1.83; 3 trials, 837 participants; [Analysis 4.1](#CD007952-fig-00401){ref-type="fig"}).

#### Return to clinic for initiation or continuation of TB prophylaxis {#CD007952-sec4-0016}

Two trials assessing return to clinic for TB prophylaxis compared material incentives with education or counselling. Both are from the USA; [@CD007952-bbs2-0008] used peer counsellors to encourage homeless men and women to attend clinic after a positive test result, and [@CD007952-bbs2-0012] gave education sessions every two weeks to jail inmates to encourage attendance at a community clinic upon release.There was no significant difference between material incentives and education or peer counselling (RR 1.10, 95% CI 0.92 to 1.31; two trials, 535 participants; [Analysis 4.2](#CD007952-fig-00402){ref-type="fig"}).

#### Return to clinic for tuberculin skin test reading {#CD007952-sec4-0017}

The two trials among drug users in the USA ([@CD007952-bbs2-0003]; [@CD007952-bbs2-0004]), also had a treatment arm which received 5 to 10 minutes of motivational education .

The material incentives (USD 5 to USD 10) significantly increased the rate of return for tuberculin skin test reading compared to motivational education alone (RR 2.16, 95% CI 1.56 to 3.00; two trials, 1366 participants; [Analysis 4.3](#CD007952-fig-00403){ref-type="fig"}).

### Potential effect modifiers {#CD007952-sec3-0025}

The most commonly reported potential effect modifier was educational status. Six trials assessed this and no effect on outcomes was noted ([@CD007952-bbs2-0003]; [@CD007952-bbs2-0004]; [@CD007952-bbs2-0005]; [@CD007952-bbs2-0008]; [@CD007952-bbs2-0010]; [@CD007952-bbs2-0012]). In one trial, it was noted that the following groups had significantly lower treatment success rates: patients who were unemployed (compared to those who were employed); children older than 13 years (compared to children younger than 13 years); men (compared to women); and patients with smear negative TB (compared to patients with smear positive TB) ([@CD007952-bbs2-0002]).

None of the studies reported their results subgrouped by HIV status. In three studies it was noted that HIV positive patients were included ([@CD007952-bbs2-0003]; [@CD007952-bbs2-0004]; [@CD007952-bbs2-0005]), and in one study it was noted that the population from which the study sample was drawn had a generally low HIV prevalence ([@CD007952-bbs2-0006]). In one trial, missing data on HIV status precluded its analysis ([@CD007952-bbs2-0002]) and in a further three trials HIV positive patients were actively excluded ([@CD007952-bbs2-0009]; [@CD007952-bbs2-0010]; [@CD007952-bbs2-0012]).

### Adverse events {#CD007952-sec3-0026}

Although adverse events due to the anti‐TB drugs administered (such as isoniazid) were noted in some trials, adverse effects of the incentives and enablers themselves were only investigated in one study ([@CD007952-bbs2-0002]). [@CD007952-bbs2-0002] recorded very few incidents of theft of vouchers, and no obvious perverse incentive effect. Patients were not inclined to stop taking their TB treatment, in order to remain ill and therefore continue receiving their vouchers.

### Cost effectiveness {#CD007952-sec3-0027}

We found one paper reporting a cost analysis, [@CD007952-bbs2-0033], which related to an included trial ([@CD007952-bbs2-0007]). This trial involved the administration of an incentive to adolescents with latent TB (in the form of a \"contingency contract\" with their parents). In a second trial, the costs of providing the intervention were described as effectively doubling the cost of treatment per patient ([@CD007952-bbs2-0006]). However, since neither of these trials demonstrated any clinical benefit with the use of these interventions, any further appraisal of the cost components is inappropriate.

Discussion {#CD007952-sec1-0006}
==========

Summary of main results {#CD007952-sec2-0011}
-----------------------

Only two trials have assessed whether material incentives and enablers can improve long‐term adherence and completion of treatment for active TB, and neither demonstrated a clear benefit (*low quality evidence*).

Three trials assessed the effects of material incentives on completion of TB prophylaxis with mixed results (*low quality evidence*). A large effect was seen with regular cash incentives given to drug users at each clinic visit in a setting with extremely low treatment completion in the control group. A second trial in prisoners found no effect with a cash incentive at the start of treatment, and a third trial from a setting with reasonably high treatment completion among teenagers found that material incentives offered by parents did not improve treatment completion compared to parental supervision alone.

However in specific populations, such as recently released prisoners, drug users, and the homeless, trials show that material incentives probably do improve one off clinic re‐attendance for initiation or continuation of anti‐TB prophylaxis (*moderate quality evidence*), and may increase the return rate for reading of tuberculin skin test results (*low quality evidence*)*.*

Overall completeness and applicability of evidence {#CD007952-sec2-0012}
--------------------------------------------------

Only two studies have evaluated the long term effects of material incentives on TB treatment outcomes. Although both were conducted in highly endemic settings, their findings are not easily generalized to wider populations because of specific contextual factors affecting each trial. In one trial, the incentive, given as a hot daily meal, was not well received by the population due to the inconvenience of attending the clinic at midday. In addition, conflict in the area affected clinic attendance and therefore participation in the trial. In the second trial, the nurses distributing the vouchers chose to \"ration\" their distribution among eligible patients and consequently decreased the power of this trial to detect a statistically significant result. These factors served to reduce the quality of the evidence presented by these trials and therefore, although neither trial showed a benefit, other trials not affected by such factors may do so. These trials demonstrate the importance of context in the conduct of research around economic interventions to improve TB treatment outcomes. Although relevant in all research, the context in which trials of social interventions take place may profoundly affect the trials. Trials of economic interventions tested in different contexts may have different results, depending on the levels of poverty, social stability, and social cohesion prevailing at the time. Such factors, whilst having an important effect on the incidence and outcomes of TB, may also have an impact on the effectiveness of economic interventions designed to reduce incidence and improve outcomes. Therefore the context of such trials, and the effect of the context on the generalizability of trial results, should be carefully considered in trial design and reporting.

The remaining studies were all conducted in traditionally hard to reach or marginal populations; injecting drug users, homeless people, prison inmates, and adolescents. It is possible that these subpopulations have different relationships with material incentives, than the general population. Economic incentives and enablers may be perceived and used differently by different groups, and although these marginalized groups are vulnerable to TB, and therefore trials in these groups remain important, the effects of economic interventions may be different in these groups compared to the broader adult population. In addition, the trials that tested economic incentives and enablers in marginalized groups took place in the USA, where the context in terms of the health services, poverty levels, social stability and social cohesion may be different from that of LMICs, where the burden of TB is highest. Thus the results of these trials may be applicable only in the setting of the USA, and only to the groups in which the trials occurred.

One important consideration in extrapolating these results to other populations is HIV. It is possible that HIV co‐infection may affect adherence to anti‐TB medications, either positively (for example, through adherence education received in the HIV programme), or negatively (for example, because illness prevents patients from attending the clinic, or because patients are already taking a number of medications for HIV). However, HIV was not considered in most of these studies. Since the risk of developing TB among patients with HIV is far higher than in those who are HIV negative ([@CD007952-bbs2-0050]), future studies on economic incentives and enablers for TB should specifically investigate the effect of HIV status on outcomes.

In some settings, health workers and managers may be concerned about giving cash to patients. Indeed, this was the rationale for the inclusion of non‐cash incentives in one trial included in this review ([@CD007952-bbs2-0004]). The reason for this concern was not described in the trial, but could be related to the expenditure of cash on unhealthy purchases. Vouchers for specified goods cannot be spent on such items and in fact were demonstrated by this trial to have a beneficial effect on return for tuberculin skin testing.

A further objection to the use of incentives may be to the rationale of \'paying the patient\' to behave in a healthy way (when it is considered the patients\' responsibility to do so). However in poor settings, it may be difficult, if not impossible, for the patient to access the clinic or pay for medicines ([@CD007952-bbs2-0039]). This acknowledgement underlies the Opportunidades Programme (now Progressa Programme) in Mexico, where patients are assisted financially in return for behaviours that will promote the health of families ([@CD007952-bbs2-0034]). This programme has been shown to have benefits in a poor population ([@CD007952-bbs2-0034]), as well as in groups of vulnerable patients in wealthier settings (such as homeless people in the USA) ([@CD007952-bbs2-0008]). Indeed, in the process evaluation of one of the included trials, nurses responsible for administering the vouchers perceived them to be helping needy patients, rather than paying them to enable a certain behaviour ([@CD007952-bbs2-0002]).

Quality of the evidence {#CD007952-sec2-0013}
-----------------------

We assessed the quality of evidence in this review using GRADE methods, and presented it in five \'Summary of findings\' tables ([Table 1](#CD007952-tbl-0001){ref-type="table"}; [Appendix 1](#CD007952-sec2-0016){ref-type="app"}; [Appendix 2](#CD007952-sec2-0017){ref-type="app"}; [Appendix 3](#CD007952-sec2-0018){ref-type="app"}; [Appendix 4](#CD007952-sec2-0019){ref-type="app"}). The evidence is generally considered to be of low or very low quality, which indicates that further research is very likely to change these estimates of effect.

The main reason for downgrading quality was the indirectness of the evidence, with only two trials from the general adult population of LMICs.

Potential biases in the review process {#CD007952-sec2-0014}
--------------------------------------

We minimised potential biases in the review process by adhering to Cochrane guidelines ([@CD007952-bbs2-0030]). We conducted comprehensive searches of both peer‐reviewed and grey literature, without limiting the searches to a specific language. Two review authors independently assessed study eligibility, extracted data, and assessed the risk of bias in each included study.

Agreements and disagreements with other studies or reviews {#CD007952-sec2-0015}
----------------------------------------------------------

Consistent with the findings of relevant previous reviews ([@CD007952-bbs2-0029]; [@CD007952-bbs2-0034]; [@CD007952-bbs2-0043]), we found that material incentives and enablers may promote the uptake of health services in certain settings. However, to the best of our knowledge, our review is the most comprehensive synthesis of existing evidence on the effects of material incentives in patients undergoing diagnostic testing for TB or receiving drug therapy to prevent or cure TB.

Authors\' conclusions {#CD007952-sec1-0007}
=====================

Material incentives may have some positive effects on adherence in the short term, particularly for marginal populations such as drug users, recently released prisoners, and the homeless, but there is currently insufficient evidence to know if they can improve the long term adherence to TB treatment.Further high‐quality studies will help explore and delineate the effects and costs of incentives and enablers to improve adherence to the long‐term treatment of active TB.Future studies should specifically investigate the role of HIV and socioeconomic status in modifying the effects of incentives for TB treatment. The possible adverse effects of incentives, such as misuse of incentives, fraudulent practices, the effect of incentives on non‐recipients, and the perverse incentive effect, should also be considered.

CSW\'s work is funded by Stellenbosch University; the National Research Foundation of South Africa; and the Effective Health Care Research Consortium (www.evidence4health.org), which is funded by the UK Department for International Development (DFID). We thank Paul Garner, Xiaolin Wei, Sally Jackson, Sarah Donegan, Anne‐Marie Stephani, and Simon Lewin for support and advice.

The academic editor for this Cochrane Review was Professor Paul Garner. The editorial base for the Cochrane Infectious Disease Group is funded by the DFID, UK, for the benefit of LMICs.

**Immediate versus deferred incentive for improving patient adherence to TB managementPatient or population:** people at high risk of developing TB **Settings:** high‐ and low‐income settings **Intervention:** immediate incentive (received on a regular basis during treatment) **Comparison:** deferred incentive (received only at end of treatment).**OutcomesIllustrative comparative risks\* (95% CI)Relative effect (95% CI)No. of participants (trials)Quality of the evidence (GRADE)Assumed riskCorresponding riskDeferred incentiveImmediateCompletion of TB prophylaxis750 per 1000832 per 1000** (735 to 930)**RR 1.11** (0.98 to 1.24)300 (1 trial)⊕⊕⊝⊝ **low**^1,2^The **assumed risk** is taken from the control group in the trial. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **CI:** confidence interval; **RR:** risk ratio.GRADE Working Group grades of evidence **High quality:** Further research is very unlikely to change our confidence in the estimate of effect. **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low quality:** We are very uncertain about the estimate.

^1^Downgraded by 1 for indirectness: this trial was conducted in specific subpopulations from the USA and the result may not be applicable to other settings. ^2^Downgraded by 1 for imprecision: the 95% CI of the estimate of effect includes both clinically important benefit and no effect.

**Cash versus non‐cash incentive for improving patient adherence to TB managementPatient or population:** people at high risk of developing TB **Settings:** high‐ and low‐income settings **Intervention:** cash incentive **Comparison:** non‐cash incentive**OutcomesIllustrative comparative risks\* (95% CI)Relative effect (95% CI)No. of participants (trials)Quality of the evidence (GRADE)Assumed riskCorresponding riskNon‐cash incentiveCashReturn for tuberculin skin test reading841 per 1000950 per 1000** (900 to 992)**RR 1.13** (1.07 to 1.18)652 (1 trial)⊕⊕⊝⊝ **low**^1^**Completion of TB prophylaxis638 per 1000804 per 1000** (651 to 995)**RR 1.26** (1.02 to 1.56)141 (1 trial)⊕⊕⊝⊝ **low**^1^The **assumed risk** is taken from the control group in the trial. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **CI:** confidence interval; **RR:** risk ratio.GRADE Working Group grades of evidence **High quality:** Further research is very unlikely to change our confidence in the estimate of effect. **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low quality:** We are very uncertain about the estimate.

^1^Downgraded by 2 for indirectness: these trials were conducted in specific subpopulations from the USA and the results may not be applicable to other settings.

**Comparison of different values of cash incentives for improving patient adherence to TB managementPatient or population:** people at high risk of developing TB **Settings:** high‐ and low‐income settings **Intervention:** higher cash value (USD 10) **Comparison:** lower cash value (USD 5)**OutcomesIllustrative comparative risks\* (95% CI)Relative effect (95% CI)No. of participants (trials)Quality of the evidence (GRADE)Assumed riskCorresponding risklower cash valuehigher cash valueReturn for tuberculin skin test reading858 per 1000927 per 1000** (867 to 995)**RR 1.08** (1.01 to 1.16)404 (1 trial)⊕⊕⊝⊝ **low**^1^The **assumed risk** is taken from the control group in the trial. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **CI:** confidence interval; **RR:** risk ratio.GRADE Working Group grades of evidence **High quality:** Further research is very unlikely to change our confidence in the estimate of effect. **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low quality:** We are very uncertain about the estimate.

^1^Downgraded by 2 for indirectness: one trial conducted in a specific subpopulation from the USA and the result may not be applicable to other settings.

**Incentives versus educational or motivational interventions for improving patient adherence to anti‐TB treatmentPatient or population:** patients at high risk of developing TB **Settings:** high‐ and low‐income settings **Intervention:** an incentive **Comparison:** any educational or motivational intervention**OutcomesIllustrative comparative risks\* (95% CI)Relative effect (95% CI)No. of participants (trials)Quality of the evidence (GRADE)Assumed riskCorresponding riskany other interventionmaterial incentivesReturn for tuberculin skin test reading429 per 1000927 per 1000** (669 to 1000)**RR 2.16** (1.56 to 3.00)1366 (2 trials)⊕⊕⊝⊝ **low**^1,2^**Return to clinic to start or continue treatment381 per 1000419 per 1000** (351 to 499)**RR 1.10** (0.92 to 1.31)535 (2 trials)⊕⊕⊝⊝ **low**^2,3^**Completion of prophylaxis for latent TB444 per 1000462 per 1000** (262 to 813)**RR 1.04** (0.59 to 1.83)837 (3 trials)⊕⊕⊝⊝ **low**^2,4^The **assumed risk** is taken from the control group in the trial. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **CI:** confidence interval; **RR:** risk ratio.GRADE Working Group grades of evidence **High quality:** Further research is very unlikely to change our confidence in the estimate of effect. **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low quality:** We are very uncertain about the estimate.

^1^Downgraded by 1 for risk of bias: neither study adequately described the method of randomization. ^2^Downgraded by 1 for indirectness: these trials were conducted in specific subpopulations from the USA and the result may not be applicable to other settings. ^3^Downgraded by 1 for imprecision: the 95% CI includes what may be clinically important benefits and no effect. ^4^Downgraded by 1 for inconsistency: two studies found no suggestion of a benefit with the incentive, and just one study found a clinically and statistically significant benefit in drug users.

Comparison 1Incentive versus routine careOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Treatment success (completion or cure)](#CD007952-fig-00101){ref-type="fig"}Analysis 1.1Comparison 1 Incentive versus routine care, Outcome 1 Treatment success (completion or cure).24356Risk Ratio (Fixed, 95% CI)1.04 \[0.97, 1.13\][2 Completion of TB prophylaxis](#CD007952-fig-00102){ref-type="fig"}Analysis 1.2Comparison 1 Incentive versus routine care, Outcome 2 Completion of TB prophylaxis.3Risk Ratio (M‐H, Random, 95% CI)Totals not selected[3 Clinic visit to start or continue TB prophylaxis](#CD007952-fig-00103){ref-type="fig"}Analysis 1.3Comparison 1 Incentive versus routine care, Outcome 3 Clinic visit to start or continue TB prophylaxis.3595Risk Ratio (M‐H, Fixed, 95% CI)1.58 \[1.27, 1.96\][4 Return for tuberculin skin test results](#CD007952-fig-00104){ref-type="fig"}Analysis 1.4Comparison 1 Incentive versus routine care, Outcome 4 Return for tuberculin skin test results.21371Risk Ratio (M‐H, Random, 95% CI)2.16 \[1.41, 3.29\]

Comparison 2Immediate versus deferred incentiveOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Completion of TB prophylaxis](#CD007952-fig-00201){ref-type="fig"}Analysis 2.1Comparison 2 Immediate versus deferred incentive, Outcome 1 Completion of TB prophylaxis.1300Risk Ratio (M‐H, Fixed, 95% CI)1.11 \[0.98, 1.24\]

Comparison 3Cash incentive versus non‐cash incentiveOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Completion of TB prophylaxis](#CD007952-fig-00301){ref-type="fig"}Analysis 3.1Comparison 3 Cash incentive versus non‐cash incentive, Outcome 1 Completion of TB prophylaxis.1141Risk Ratio (M‐H, Fixed, 95% CI)1.26 \[1.02, 1.56\][2 Return for tuberculin skin test reading](#CD007952-fig-00302){ref-type="fig"}Analysis 3.2Comparison 3 Cash incentive versus non‐cash incentive, Outcome 2 Return for tuberculin skin test reading.1652Risk Ratio (M‐H, Fixed, 95% CI)1.13 \[1.07, 1.19\]

Comparison 4Incentives versus any other interventionOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Completion of TB prophylaxis](#CD007952-fig-00401){ref-type="fig"}Analysis 4.1Comparison 4 Incentives versus any other intervention, Outcome 1 Completion of TB prophylaxis.3837Risk Ratio (M‐H, Random, 95% CI)1.04 \[0.59, 1.83\][2 Clinic visit to start or continue TB prophylaxis](#CD007952-fig-00402){ref-type="fig"}Analysis 4.2Comparison 4 Incentives versus any other intervention, Outcome 2 Clinic visit to start or continue TB prophylaxis.2535Risk Ratio (M‐H, Fixed, 95% CI)1.10 \[0.92, 1.31\][3 Return for tuberculin skin testing](#CD007952-fig-00403){ref-type="fig"}Analysis 4.3Comparison 4 Incentives versus any other intervention, Outcome 3 Return for tuberculin skin testing.21366Risk Ratio (M‐H, Random, 95% CI)2.16 \[1.56, 3.00\]

Comparison 5Different values of cash incentiveOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Return for tuberculin skin test reading](#CD007952-fig-00501){ref-type="fig"}Analysis 5.1Comparison 5 Different values of cash incentive, Outcome 1 Return for tuberculin skin test reading.1404Risk Ratio (M‐H, Fixed, 95% CI)1.08 \[1.01, 1.16\]

**DateEventDescription**4 September 2015AmendedTypo corrected in abstract and in main text.

Protocol first published: Issue 3, 2009 Review first published: Issue 1, 2012

**DateEventDescription**19 August 2015New search has been performedWe performed a search update and identified two potentially eligible studies. We included one new study and excluded the other.\
Although we had originally intended to include only studies focusing on adults aged 16 years and over, we dropped this age limitation as a few trials were found that included children or adolescents.19 August 2015New citation required but conclusions have not changedReview updated June 2015

.

Characteristics of included studies \[ordered by study ID\] {#CD007952-sec2-0022}
===========================================================

[@CD007952-bbs2-0001]MethodsIndividually RCT, factorial design\
Duration of enrolment: June 1995 to August 1997ParticipantsNumber enrolled: 300\
Inclusion criteria: injection drug users over 18 years old, with tuberculin skin test reading of more than 5 mm induration if HIV positive or more than 10 mm if HIV negative, on preventive treatment for TB\
Exclusion criteria: evidence of active TB, history of serious adverse reaction to INH (isoniazid) treatment, previous INH treatment for ≥ 6 months, serum ALT elevated \> 5 times normal levels, or HIV disease with CD4 count \< 200/mm³. (Isoniazid is a standard TB medication used for both prophylaxis and treatment of active TB)InterventionsAll participants were randomly assigned to receive either:\
A an immediate USD 10 stipend per month (for each monthly appointment kept); orA deferred amount, equal to USD 10 for each monthly appointment kept.\
The immediate payment was given at the end of each month when the patient had completed a routine assessment for adherence and drug toxicity. The deferred payment was credited each month a patient in this group completed assessment for adherence and toxicity, but payment was made when treatment was completed or when the patient withdrew from the study.\
Each arm was on prophylaxis for TB.OutcomesCompletion of 6 months of INH preventive treatment (reporting for each of 6 monthly visits and taking at least 80% of medication).NotesIndependent of the material incentive, all patients were randomly assigned to directly observed preventive therapy (i.e. outreach meeting with a nurse twice a week; peer support counselling (i.e. monthly support group meetings); or routine care (i.e. monthly clinic visits).\
Trial location: Baltimore, USA\
Setting: community‐based TB clinic\
Source of funding: National Institute on Drug Abuse (DA 08992) and the National Institute of Allergy and Infectious Diseases (AI 01637)***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskSequence generation performed by computer algorithm.Allocation concealment (selection bias)Unclear riskNo description of allocation concealment was given.Blinding (performance bias and detection bias) All outcomesUnclear riskNot known if outcome assessors were blinded.Incomplete outcome data (attrition bias) All outcomesLow riskNumbers presented for whole group and each arm, intention‐to‐treat (ITT) analysis. Withdrawals included \"failure to return (37 patients), voluntary withdrawal (4)\...and other reasons (13)\". These do not seem to be related to the material incentives.Selective reporting (reporting bias)Unclear riskStudy protocol not available and there is no earlier methods paper listing the pre‐specified outcomes.Other biasLow riskThe study appears to be free of other bias.[@CD007952-bbs2-0002]MethodsCluster RCT using primary health care clinics as clusters\
Duration: July 2009 to March 2010ParticipantsNumber enrolled: 20 clinics randomized, enrolling 4091 TB patients\
Inclusion criteria: all patients diagnosed with pulmonary, drug sensitive TB, and starting TB treatment during the study period. Includes both adults and children\
Exclusion criteria: none statedInterventionsPrimary health care clinics were randomized to provide:\
Standard TB care plus material incentives: A voucher valued at ZAR120 (approximately USD 15) was offered to patients by nurses every month on collection of their TB treatment to a maximum of eight months. Patients were advised to redeem the voucher for healthy foodstuffs but this was not monitored;Standard TB care.OutcomesPrimary outcome: TB treatment success defined as cure or treatment completion\
Secondary outcomes:\
Default;Treatment interrupted;TB treatment failure;Multi‐drug resistant TB;Deaths.NotesTrial location: KwaZulu‐Natal, South Africa\
Setting: urban and rural primary healthcare clinics\
Source of funding: Research Programme of the National Department of Health (South Africa), the Tuberculosis Control Assistance Program (TP CAP, the Netherlands), the Wellcome Trust (UK)***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low risk\"The 20 study clinics were randomly selected from the 26 eligible clinics stratified by district. Within the two districts, the study clinics were randomly assigned in a 1:1 ratio, using a randomisation list generated by the study statistician.\"Allocation concealment (selection bias)Low risk\"Clinics were allocated to intervention or control groups by the study statistician and no changes were made to this allocation\".\
Personal communication with the trial author: The study statistician had no knowledge of the clinic sites being randomized and was based Cape town.Blinding (performance bias and detection bias) All outcomesHigh risk\"Because of the nature of the intervention, no blinding was possible.\"\
\"Data extractors were not blinded as it was considered neither practical nor feasible to conceal from them the intervention status of the clinic.\"Incomplete outcome data (attrition bias) All outcomesLow riskThere was no loss of clusters.\
Outcome data were unavailable on 0.2% of patients in intervention clinics and 0.7% of patients in control clinics.Selective reporting (reporting bias)Low riskNo evidence of selective outcome reporting identified.Other biasUnclear riskFidelity to the intervention was poor, with only 31.5% of patients receiving their vouchers for most of their treatment. More than a third (36.2%) of eligible patients did not receive a voucher at all and the remainder received vouchers for between 1 and 3 months of treatment. This low fidelity was attributed largely to nurses\' rationing of the vouchers to those whom they felt were more deprived and therefore more deserving.[@CD007952-bbs2-0003]MethodsIndividually RCT\
Duration: April 1994 to August 1995ParticipantsNumber enrolled: 1004\
Inclusion criteria: injection drug and crack cocaine users, who had tuberculin skin tests and were required to return for the reading\
Exclusion criteria: none statedInterventionsParticipants were divided into 6 arms, which received the following interventions:\
5 to 10 minute session of motivational education;5 to 10 minute session of motivational education plus USD 10 on return for tuberculin skin test reading;5 to 10 minute session of motivational education plus USD 5 on return for tuberculin skin test reading;USD 10 on return for tuberculin skin test reading;USD 5 on return for tuberculin skin test reading;Routine care.OutcomesReturn for tuberculin skin test reading within 96 hoursNotesTrial location: Long Beach, California, USA\
Setting: urban research clinic\
Source of funding: National Institute on Drug Abuse (grant RO1‐DA08799)***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskMethod of randomization not described.Allocation concealment (selection bias)Unclear riskNot described.Blinding (performance bias and detection bias) All outcomesUnclear riskNot described.Incomplete outcome data (attrition bias) All outcomesLow riskNo omissions from final analysis.\
1004 enrolled, ITT analysis.Selective reporting (reporting bias)Unclear riskStudy protocol not available and there is no earlier methods paper listing the pre‐specified outcomes.Other biasLow riskThe study appears to be free of other bias.[@CD007952-bbs2-0004]MethodsIndividually RCT\
Duration: September 1995 to September 1997ParticipantsNumber enrolled: 1078\
Inclusion criteria: injection drug and crack cocaine users who had tuberculin skin tests and were required to return for the reading (age restrictions not specifically stated but all participants were over age of 18 years)\
Exclusion criteria: participation in group\'s previous studiesInterventionsUSD 10 on return for TB skin test reading;Grocery store coupons worth USD 10 on return for TB skin test reading;Patient\'s choice of bus passes or coupons for fast food restaurant worth USD 10 on return for TB skin test reading;Motivational education session of 5 to 10 minutes;Routine care.OutcomesReturn for TB skin test reading within 96 hoursNotesStudy was a follow‐up to [@CD007952-bbs2-0003] ‐ trial authors wanted to test effectiveness of non‐cash incentives, as they felt health departments might object to giving cash out to patients as this was considered controversial.\
Trial location: Long Beach, California, USA\
Setting: urban research clinic\
Source of funding: National Institute on Drug Abuse (grant RO1‐DA08799)***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNo description of method of randomization.Allocation concealment (selection bias)Unclear riskNot described.Blinding (performance bias and detection bias) All outcomesUnclear riskNot described.Incomplete outcome data (attrition bias) All outcomesLow riskNo omissions from final analysis. 1078 randomized, ITT analysis.Selective reporting (reporting bias)Unclear riskStudy protocol not available and there is no earlier methods paper listing the pre‐specified outcomes.Other biasLow riskThe study appears to be free of other bias.[@CD007952-bbs2-0005]MethodsIndividually RCT\
Duration: April 1994 to September 1997 (recruitment period)ParticipantsNumber enrolled: 169\
Inclusion criteria: injection drug or crack cocaine users, needing INH treatment for TB prophylaxis\
Exclusion criteria: active TB or medical contraindications to the use of isoniazidInterventionsTwice weekly directly observed therapy (DOT) by study outreach worker at location chosen by patient, plus USD 5 per visit;Twice weekly DOT by study outreach worker at location chosen by patient;Twice weekly DOT at study site plus USD 5 per visit.\
Participants in both arms received INH prophylaxis.OutcomesCompletion of course of INH (6 months if patient HIV negative, 12 months if patient HIV positive). Also percentage of medications taken on time (all doses in all arms were directly observed).NotesTrial location: Long beach, California, USA\
Setting: urban research clinic\
Source of funding: National Institute on Drug Abuse (grant RO1‐DA08799)***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRandomization in blocks of 18, assumed to have been done by computer.Allocation concealment (selection bias)Low riskAllocation was kept in \"numbered, opaque, sealed envelopes\" and \"staff \...were unaware of block size\".Blinding (performance bias and detection bias) All outcomesUnclear riskNot described.Incomplete outcome data (attrition bias) All outcomesLow risk169 patients randomized. Six excluded from analysis for medical reasons which were unlikely to have been related to the study outcome. ITT analysis.Selective reporting (reporting bias)Unclear riskStudy protocol not available and there is no earlier methods paper listing the pre‐specified outcomes.Other biasLow riskThe study appears to be free of other bias.[@CD007952-bbs2-0006]MethodsIndividually RCT conducted at three sites in Dili, Timor Leste\
Duration: enrolment 16 March to 9 November 2005; follow‐up continued until July 2006ParticipantsPatients with newly diagnosed pulmonary TB, both positive and negative results on sputum tests\
Eligible: 833 (563 excluded)\
Randomized: 270 (133 control, 137 intervention group)\
Most participants were poor, malnourished men living close to the clinicsInterventionsNutritious, culturally appropriate daily meal (weeks 1 to 8) and food packages (weeks 9 to 32);Control group given nutritional advice.\
Both groups received standard TB treatmentOutcomesPrimary outcomes: completion of treatment, including cure\
Secondary outcomes: adherence to treatment, weight gain, and clearance of sputum smearsNotesOutbreak of civil conflict in the country three months before completion of study disrupted service delivery and access of patients to health care (70% of the population were displaced). However, it is likely that this affected intervention and control groups similarly.\
Most participants were poor and malnourished men who lived close to the clinics and this may limit the external generalizability of the study.\
Substantial missing data for intermediate outcomes implies that participants did not attend clinics regularly. Also, intervention was not well received by many participants as it was inconvenient to attend the clinics at midday for the meal (this was also the reason for a high number of patients\' refusal to participate in the trial). 70% of participants had negative smear results, which means that cure could not be objectively verified. Adherence was not objectively assessed.\
Adverse events: None necessitated stopping treatment. Itch with or without rash was more than twice as likely to occur in the intervention group (RR 2.27, 95% CI 1.20 to 4.26).***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer generated random allocation sequence with randomly varying block sizes (done by independent statistician using STATA). Allocation was stratified by community health clinic and by diagnosis of TB (positive or negative smear).Allocation concealment (selection bias)Low riskConcealed from all investigators with sequentially numbered opaque sealed envelopes prepared distant from study site.Blinding (performance bias and detection bias) All outcomesUnclear riskBlinding of participants and treatment providers not done, but independent observer who determined the primary outcome was blinded.Incomplete outcome data (attrition bias) All outcomesLow riskAll participants received allocated intervention and loss to follow‐up (transfer to another clinic during treatment) was very small (1% in intervention group and 4% in control group). ITT analysis.Selective reporting (reporting bias)Unclear riskStudy protocol not available and there is no earlier methods paper listing the pre‐specified outcomes.Other biasUnclear riskTwo important factors affected the conduct of the trial and undermined the potential effectiveness of the intervention. The first was civil conflict that arose during the last few months of the trial, resulting in the displacement of approximately 70% of the local population, and dramatically increasing the rate of default from treatment. The second factor was the timing of the provision of meals to patients in the intervention group. Many patients found the provision of meals, together with treatment, at midday inconvenient, and this may have become a barrier to adherence to treatment.[@CD007952-bbs2-0007]MethodsIndividually RCT.\
Duration: not statedParticipantsNumber enrolled: 794\
Inclusion criteria: adolescents aged 11 to 19 years who needed treatment for latent TB infection.\
Exclusion criteria: not statedInterventionsPeer counselling (at least once every two weeks);Incentive (participant‐parent contingency contract, where parent and patient negotiated a reward for adherence to treatment. This was provided by the parent and given at a frequency negotiated by the parent and participant). Examples of incentives included a special meal at home, going out to eat, clothing, going to movies or renting a video, or anything agreeable to both parent and adolescent;Combined peer counselling and incentive (participant‐parent contingency contract);Usual care.\
Participants in intervention and control arms received INH prophylaxis.OutcomesCompletion of 6 months of INH prophylaxis; measured using the discharge summary recorded in the patient\'s medical chart.NotesTrial location: Los Angeles County, USA\
Setting: urban community based clinics\
Source of funding: National Heart, Lung and Blood Institute (ROI‐55770).***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskNot described.Allocation concealment (selection bias)Unclear riskNot described.Blinding (performance bias and detection bias) All outcomesUnclear riskNot described.Incomplete outcome data (attrition bias) All outcomesLow riskAuthors state that ITT model was used (pg 570). 794 adolescents enrolled and analysed. No omissions from final analysis.Selective reporting (reporting bias)Unclear riskStudy protocol not available and there is no earlier methods paper listing the pre‐specified outcomes.Other biasLow riskOver and above the interventions described above, patients were interviewed three times during the study and at each interview received USD 15. The additional interest in the participants, plus the cash which may have acted as a further incentive to adhere, may be regarded as interventions in themselves. However, this applied to all participants and would not have introduced bias.[@CD007952-bbs2-0008]MethodsIndividually RCT\
Duration: June 1992 to April 1994ParticipantsNumber enrolled: 244\
Inclusion criteria: Homeless \"men and women\", age not specified (but all over 18 years in results), who had a tuberculin skin test and were required to attend a clinic to initiate treatment for latent or active TB\
Exclusion criteria: Recent investigation for TBInterventionsPeer health advisers plus usual care (advisers accompanied patients to clinics and assisted with filling out forms etc);Incentive of USD 5 cash if participant came to clinic within 3 weeks of randomization plus usual care;Usual care (appointment at TB clinic plus a bus token for transport to clinic).OutcomesAttendance at clinic appointment within three weeks of positive reading of tuberculin skin test.NotesSecond phase of this study reported in Tulsky et al 2000.\
Trial location: San Fransisco, California, USA\
Setting: urban community based TB clinic (attached to San Francisco General Hospital)\
Source of funding: Kaiser Family Foundation, Acquired Immunodeficiency Syndrome Clinical Research Center, San Francisco, California; Universitywide Acquired Immunodeficiency Syndrome Research Program, University of California; and by grant R01‐DA04363‐07 from the National Institute on Drug Abuse, Bethesda, MD.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low risk\"treatment group was assigned by sampling without replacement from blocks of nine\". Assumed to be done by computer.Allocation concealment (selection bias)Unclear riskNot described.Blinding (performance bias and detection bias) All outcomesUnclear riskNot described.Incomplete outcome data (attrition bias) All outcomesLow risk244 patients randomized, 244 analysed.Selective reporting (reporting bias)Unclear riskStudy protocol not available and there is no earlier methods paper listing the pre‐specified outcomes.Other biasLow riskThe study appears to be free of other bias.[@CD007952-bbs2-0009]MethodsIndividually RCT\
Duration: June 1992 to May 1995 (recruitment period June 1992 to December 1994, plus 6 months of patient follow‐up time).ParticipantsNumber enrolled: 118\
Inclusion criteria: homeless adults, with positive tuberculin skin test or credible history of prior positive tuberculin skin test but no follow‐up for this in the 6 months prior to the study\
Exlusion criteria: receiving treatment or prophylaxis for TB at the time of the study, or HIV positiveInterventionsUsual care (self‐supervised daily dosing with INH and monthly clinic visits for assessment and refill of tablets);Taking of 900 mg INH directly observed at each of two weekly visits to study site; plus an incentive of USD 5 cash;Peer health advisor (who directly supervised taking of treatment twice weekly, accompanied patient to clinic and looked for the patient if lost to follow‐up).\
Participants in intervention and control arms received INH prophylaxis.OutcomesCompletion of 6 months of INH preventive treatment as documented in patients\' clinic charts; number of months of INH dispensed.NotesTrial location: San Francisco, California, USA\
Setting: community‐based TB clinic\
Source of funding: not stated***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskBlock randomization used, therefore allocation sequence assumed to have been generated by computer.Allocation concealment (selection bias)Unclear riskNot described.Blinding (performance bias and detection bias) All outcomesUnclear riskNot described.Incomplete outcome data (attrition bias) All outcomesLow riskOf 330 patients randomized, 195 found to require further evaluation and 37 needed further diagnostic tests (sputum cultures and liver function tests). Of 121 who were prescribed INH, 118 were analysed ‐ 3 were excluded from study because of \"toxic effects of INH\". These reasons unlikely to be related to final outcome.Selective reporting (reporting bias)Unclear riskStudy protocol not available and there is no earlier methods paper listing the pre‐specified outcomes.Other biasLow riskThe study appears to be free of other bias.[@CD007952-bbs2-0010]MethodsIndividually RCT.\
Duration: May 1996 to May 1998 (based on recruitment period of May 1996 to December 1997, plus 6 months for patient follow‐up).ParticipantsNumber enrolled: 119 (85% male; median age 41 years, range 21 to 79)\
Inclusion criteria: homeless adults who were eligible for preventive TB treatment. Adults who were \"truly homeless\" (living in street and shelter dwellings) and those who were \"marginally housed\" (living in residential hotels) were recruited into the study\
Exclusion criteria: active TB or HIV positiveInterventionsUSD5 cash incentive for each twice weekly appointment kept;Non‐cash incentive with face value of USD 5 for each twice weekly appointment kept (patients could choose between fast food or grocery store coupons, phone cards or bus tokens).\
Participants in intervention and control arms received INH prophylaxis.OutcomesCompletion of preventive treatment (assessed by reviewing TB clinic records);Length of time needed to look for participants who had missed scheduled appointments and didn\'t respond to letters or phone calls. (A tracking form including names and mailing addresses of family, friends, and case workers was completed for each participant. After the first missed appointment, staff made phone calls and sent reminder letters. If the participant did not attend the next scheduled visit, outreach efforts were initiated and were guided by the information on the tracking form).NotesAs the cash incentive arm did so much better than the non incentive arm in the study performed by this group previously ([@CD007952-bbs2-0009]), the trial authors felt it would be unethical to continue to randomize one group to no incentive.\
Trial location: San Francisco, California, USA\
Setting: urban, community‐based TB clinic\
Source of funding: National Heart, Lung, and Blood Institute (grant HL55729) and the National Institute of Mental Health (grant MH54907).***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskSequence was generated \"\...from a list of randomly generated numbers\".Allocation concealment (selection bias)Unclear risk\"\...numbers previously sealed into individual envelopes and selected in consecutive order\". Unclear if these envelopes were opaque.Blinding (performance bias and detection bias) All outcomesLow risk\"TB clinic physicians were blinded with respect to the results of the randomisation\".Incomplete outcome data (attrition bias) All outcomesLow risk141 patients randomized but 16 not prescribed INH (4 in cash incentive arm, 12 in non‐cash incentive arm). Reasons for exclusion clinical and unlikely to be related to allocation. 6 patients censored (5 for clinical reasons, 1 because died in hotel fire). Again, reasons for exclusion unlikely to be related to allocation or outcome. 119 patients analysed.Selective reporting (reporting bias)Unclear riskStudy protocol not available and there is no earlier methods paper listing the pre‐specified outcomes.Other biasHigh riskThe study groups were not the same with respect to their primary housing in the year prior to the study. In the cash incentive arm, 23% had lived in a shelter or on the street, whilst 41% of the non‐cash incentive arm had done so.[@CD007952-bbs2-0011]MethodsIndividually RCT\
Duration: one year (1996)ParticipantsNumber enrolled: 79 (98% male, mean age 32.0 years)\
Inclusion criteria: jail inmates eligible for INH prophylaxis for latent TB infection\
Exclusion criteria: unable to speak English or Spanish, or sequestration from jail population due to violence or mental illnessInterventionsPromise of USD 5 cash incentive (to be provided) on making first visit to community TB clinic to continue INH prophylaxis after release from jail plus standardised TB education;Standardised TB education (about TB and the importance of taking INH prophylaxis).\
Participants in intervention and control arms received INH prophylaxis.OutcomesAttendance at first visit to community TB clinic to continue INH prophylaxis after release from jailNotesTrial location: San Francisco, California, USA\
Setting: Prison\
Source of funding: Academic Senate of the University of California, San Francisco.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRandomization done using table of random numbers.Allocation concealment (selection bias)Low riskPreviously sealed, ordered, opaque envelopes used.Blinding (performance bias and detection bias) All outcomesLow riskResearch assistants collecting clinic data (as to whether participant attended first appointment or not) were blinded as to participants\' assignments.Incomplete outcome data (attrition bias) All outcomesLow riskOf the 79 inmates enrolled in the study, 18 remained in prison for the full duration of their INH treatment (and so were never required to present at a community TB clinic). 61 were analysable, and there were no differences between treatment allocations in this group. \"Data were rechecked for internal validity and there were no differences by study group in any of the variables collected for this analytic sample of 61 persons\" (pg 508).Selective reporting (reporting bias)Unclear riskStudy protocol not available and there is no earlier methods paper listing the pre‐specified outcomes.Other biasLow riskThe study appears to be free of other bias.[@CD007952-bbs2-0012]MethodsIndividually RCT\
Duration of enrolment: 1 March 1998 to 31 May 1999ParticipantsNumber enrolled: 558 (82% male; median age 28.5 years in incentive arm, 29.7 years in routine care arm, and 29.5 years in education arm)\
Inclusion criteria: Jail inmates with latent TB infection, eligible for and agreeable to INH prophylaxis\
Exclusion criteria: HIV positive, not able to speak English or Spanish, assessed by Sherriff\'s personnel to be violent, or by mental health staff to have a serious psychiatric illnessInterventionsPromise of incentive (USD 25 equivalent in food or transportation vouchers), provided at the first visit to the community TB clinic after release from jail;Education, provided every two weeks whilst in jail;Usual care (neither intervention).OutcomesAttendance at first visit to community TB clinic to continue INH prophylaxis within one month after release from jail;Completion of full course of INH treatment.NotesHIV positive patients on INH prophylaxis receive very different programme of treatment, including incentives.\
Trial location: San Francisco, California, USA\
Setting: prison\
Source of funding: National Institute of Nursing Research, National Institutes of Health, Bethesda, Md. (grant R01 NR04456).***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRandomization done using table of random numbers.Allocation concealment (selection bias)Low riskOrdered, opaque, sealed envelopes used.Blinding (performance bias and detection bias) All outcomesLow riskResearch assistants collecting clinic data (as to whether participant attended first appointment or not) were blinded as to participants\' assignments.Incomplete outcome data (attrition bias) All outcomesLow riskOf 558 inmates enrolled, 48 discontinued INH treatment whilst in jail, and 185 completed INH treatment whilst in jail. Thus 325 were eligible for analysis. There were no differences between study group in either the 325 analysable patients or 558 initially enrolled patients. Reasons for exclusion from analysis not likely to be related to final outcome. ITT analysis for those released while taking INH.Selective reporting (reporting bias)Unclear riskStudy protocol not available and there is no earlier methods paper listing the pre‐specified outcomes.Other biasLow riskThe study appears to be free of other bias.

Characteristics of excluded studies \[ordered by study ID\] {#CD007952-sec2-0023}
===========================================================

StudyReason for exclusion[@CD007952-bbs2-0013]Not a RCT; essentially two cross‐sectional studies where first group was not given incentive and second group was.[@CD007952-bbs2-0014]Not a RCT, as allocation to treatment interventions was done by day of the week.[@CD007952-bbs2-0015]Not a RCT; allocation to receive the grocery voucher intervention was not randomized.[@CD007952-bbs2-0016]Not a RCT; essentially two cross‐sectional studies where first group was not given incentive and second group was.[@CD007952-bbs2-0017]Not a RCT; comparison group was an historical control.[@CD007952-bbs2-0018]A trial of community health worker delivered TB treatment combined with food supplements; and not a trial of food incentives per se.[@CD007952-bbs2-0019]Not a RCT, as allocation to treatment interventions was done by the last digits of the participants\' clinic numbers.[@CD007952-bbs2-0020]Both the intervention and control arms received a USD 5 cash incentive for each dose of INH prophylaxis taken. It was therefore not possible to assess the effect of the incentive in this study. The main intervention was a nurse case management programme.[@CD007952-bbs2-0021]Controlled before‐and‐after study, with no evidence of randomization to control or intervention groups. Incentives were provided to health care workers as well as patients, and the effect of patients\' incentives only was not disaggregated.

All five review authors contributed to the review, with EL taking primary responsibility. EL, SK, DS, and CSW participated in study selection, data extraction and analysis, and writing of the report. JV resolved any disputes arising during the selection of trials to include in the review, and assisted with data analysis and report writing.

Internal sources {#CD007952-sec2-0020}
================

Centre for Evidence‐based Health Care, Stellenbosch University (CSW), South Africa.

External sources {#CD007952-sec2-0021}
================

Effective Health Care Research Consortium, Stellenbosch University\'s Centre for Evidence Based Health Care, and South African Cochrane Centre (EL), South Africa.EL received a travel grant from the Effective Health Care Research Consortium, through the Centre for Evidence‐based Health Care (Stellenbosch University), to spend one week at the South African Cochrane Centre (South African Medical Research Council) and work with CSW in updating the review.

EL was the principal investigator in the new study included in the current review update ([@CD007952-bbs2-0002]). However, two review authors who were not involved with this trial (DS and CSW) independently extracted and verified data. Two Cochrane Editors provided oversight.

[^1]: Editorial Group: Cochrane Infectious Diseases Group.

[^2]: ^1^Downgraded by 2 for indirectness: these two trials evaluated specific interventions amongst specific populations, and problems with the acceptability and implementation of the intervention in both trials limit the generalizability of this finding of no effect. ^2^Downgraded by 1 for indirectness: these trials were conducted in specific subpopulations from the USA (drug users, recently released prisoners, and adolescents), and the result may not be applicable in other settings. ^3^Downgraded by 1 for inconsistency: two studies found no suggestion of a benefit with the incentive, and one study found a clinically and statistically significant benefit in drug users in a setting where adherence without incentives was very low. ^4^Downgraded by 1 for indirectness: these trials were conducted in specific subpopulations from the USA (the homeless or recently released prisoners), and the result may not be applicable in other settings. ^5^Downgraded by 1 for risk of bias: neither study adequately described the method of randomization. ^6^Downgraded by 1 for indirectness: these trials were conducted in specific subpopulations from the USA (drug users), and the result may not be applicable in other settings.

[^3]: ^a^Cochrane Infectious Diseases Group Specialized Register. ^b^Search terms used in combination with the search strategy for retrieving trials developed by Cochrane ([Lefebvre 2011](Lefebvre 2011)); Upper case: MeSH or EMTREE heading; Lower case: free text term.
